Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf(Dana-Farber Brigham Cancer Center), Hong Zhang(Memorial Sloan Kettering Cancer Center), Carlos H. Barrios(Pontifícia Universidade Católica do Rio Grande do Sul), Shigehira Saji(Fukushima Medical University), Kyung Hae Jung(University of Ulsan), Roberto Hegg(Universidade de São Paulo), Andreas Koehler(Praxis für Hämatologie und Onkologie), Joohyuk Sohn(Yonsei University Health System), Hiroji Iwata(Aichi Cancer Center), Melinda L. Telli(Stanford University), Cristiano Ferrario(Jewish General Hospital), Kevin Punie(KU Leuven), Frédérique Penault-Llorca(Inserm), Shilpen Patel, Anh Nguyen Duc(Roche (Switzerland)), Mario Liste-Hermoso(Roche (Switzerland)), Vidya Maiya, Luciana Molinero, Jane Yuet Ching Hui, Nadia Harbeck(Ludwig-Maximilians-Universität München)
Cited by 1,053Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis